Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 11:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,221 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease, Obesity
Interventions
Amlexanox, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Parkinson Disease
Interventions
Hydrogen, Placebo oral tablet
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
40 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Active, not recruiting Phase 1Phase 2 Interventional Results available

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

NCT04496960
Conditions
Sjogren's Syndrome
Interventions
tofacitinib, Placebo
Drug · Other
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers

NCT03291782
Conditions
Gout
Interventions
D-0120
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Conditions
Nonintubated Acute Respiratory Distress Syndrome (ARDS), Pathogen-associated Lung Injury
Interventions
Vadadustat 900mg, Vadadustat 1200mg, Placebo
Drug
Lead sponsor
Paul Potnuru
Other
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Houston, Texas
Conditions
Diabetes Mellitus, Type 2
Interventions
high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
112
States / cities
Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more
Conditions
Huntington Disease
Interventions
PTC518, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
25 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
La Jolla, California • Nashville, Tennessee • Houston, Texas + 1 more
Conditions
Helicobacter Pylori
Interventions
Bismuth quadruple therapy with optimized proton pump inhibitor (PPI), Bismuth quadruple therapy with standard proton pump inhibitor (PPI), Clarithromycin triple therapy with optimized proton pump inhibitor (PPI), Clarithromycin triple therapy with standard PPI, Standard bismuth quadruple therapy
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
San Diego, California
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Antecedent Metabolic Health and Metformin Aging Study

NCT04264897
Conditions
Aging, Insulin Sensitivity, Chronic Disease, Mitochondria, Insulin Resistance
Interventions
Metformin, Placebo oral tablet
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
40 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Madison, Wisconsin
Conditions
Hypertension
Interventions
Azilsartan Medoxomil, Olmesartan, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
46
States / cities
Huntsville, Alabama • Ozark, Alabama • Mesa, Arizona + 43 more
Conditions
Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions
Brexpiprazole, OPC-34712, Placebo Oral Tablet
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
37
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Bellflower, California + 25 more
Conditions
Obesity, Healthy
Interventions
Ileocolonic-release conjugated bile acid, Placebo
Dietary Supplement · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 3 Interventional Results available

Treatment of Erectile Dysfunction II

NCT01037218
Conditions
Erectile Dysfunction
Interventions
Udenafil, Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
19 Years and older · Male only
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
40
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tempe, Arizona + 36 more
Conditions
Calcium Phosphate Kidney Stones
Interventions
OHCit- standard dose, Potassium Citrate, Placebo, OHCit- low dose
Dietary Supplement · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Completed Not applicable Interventional Results available

Dalfampridine and Gait in Spinocerebellar Ataxias

NCT01811706
Conditions
Spinocerebellar Ataxias Type 1, Spinocerebellar Ataxias Type 2, Spinocerebellar Ataxias Type 3, Spinocerebellar Ataxias Type 6
Interventions
Dalfampridine, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Genetics Disease, Type2 Diabetes, Heart Failure
Interventions
Sitagliptin 100mg, Placebo Oral Tablet
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 3 Interventional Results available

Imatinib (QTI571) in Pulmonary Arterial Hypertension

NCT00902174
Conditions
Pulmonary Arterial Hypertension
Interventions
imatinib mesylate, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Conditions
Parkinson's Disease
Interventions
IPX054 200 mg, CD-LD IR, IPX054 Placebo, CD-LD IR Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 23 more
Conditions
Type 2 Diabetes
Interventions
dapagliflozin, placebo, metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 79 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
111
States / cities
Bayou La Batre, Alabama • Birmingham, Alabama • Huntsville, Alabama + 107 more
Conditions
Chronic Heart Failure
Interventions
AZD5462, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Alexander City, Alabama • Northridge, California • Torrance, California + 11 more
Recruiting Early Phase 1 Interventional

Ketones, SGLT2, HFrEF

NCT06229678
Conditions
Type2diabetes, Heart Failure With Reduced Ejection Fraction
Interventions
Empagliflozin 25 MG Oral Tablet, Placebo, Acipimox 250 Mg Oral Capsule
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Statin Therapy on Adaptations to Aerobic Exercise

NCT03360916
Conditions
Cardiovascular Diseases
Interventions
Lipitor 20Mg Tablet, Lipitor 80Mg Tablet, Placebo, Exercise Program
Drug · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
35 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas